Clinical Trial Update: IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating IFx-Hu2.0 as an adjunct to pembrolizumab in advanced or metastatic Merkel cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• IFx-Hu2.0
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: TuHURA Biosciences, Inc. | Conditions: Advanced Or Metastatic Merkel Cell Carcinoma | Phase 1 | Status: RECRUITING